BioSpace News Archive

Lannett Company, Inc. (NYSE: LCI) (“Lannett” or the “Company”) today announced the pricing of $75 million aggregate principal amount of 4.50% convertible senior notes due 2026 (the “Notes”) in a private placement to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”)

cbdMD, Inc., a nationally recognized consumer cannabidiol (CBD) brand (NYSE American: YCBD), has signed a comprehensive, multi-year Partnership agreement with Life Time to bring CBD awareness and education to millions of Americans coast-to-coast.

More than one in four heart attack survivors don’t completely understand the role aspirin plays in helping prevent a second heart attack – and among those not currently taking aspirin, nearly one in five say it is because they saw a news article that made them feel they should not take aspirin, contrary to current medical guidelines.

Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announced today that it has named Andrew A. Komjathy as Chief Commercial Officer.

Today Inversago Pharma Inc., a preclinical-stage biotech company developing new CB1 blockers for the treatment of targeted metabolic disorders, announced the appointment of Dr. Caroline Fradette as Vice-President, Clinical Research.

Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA therapeutics and vaccines to create a new generation of transformative medicines for patients, announced its participation in the following upcoming investor conferences

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, provided an update on its commercialization plans for Renevia®, the Company’s facial aesthetics product, which was recently granted a Conformité Européenne (CE) Mark.

Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready autotaxin inhibitor for patients with fibrotic diseases.

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced that it has applied the CE mark to the PGDx elio™ tissue complete assay.

Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical stage immuno-oncology company developing first-in-class Superkines and Empowered Cytokines, today presented updated clinical results from its Phase 2b clinical trial of MDNA55,